Divis Laboratories Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/h8fyathght7klefoqb5akcv1.pdf

Key Takeaways


Generic API: Volume Up, Value Flat

Dr. Kiran S. Divi: "I wish to stabilize this today, but I don't have control on that. It should happen soon, we are hoping in the coming few quarters things should slowly stabilize."

Custom Synthesis & the Biosecure Act Opportunity


Peptides: From Building Blocks to Fragments

Dr. Kiran S. Divi: "The peptide building blocks we are actively supplying to the innovators and to the companies. Now we are taking one step forward and building the fragments. So, from the fragments they combine two or three fragments, and the API comes out."

Kakinada & Capex: Building for the Medium Term


Margins & the Long Normalization

Nilima Prasad Divi: "But yes, the wishful thinking is that what the historic number we had one particular year back in the day, I wouldn't say it's something that we don't desire, we are working towards it, but every product can't be that."

Supply Chain & Regulatory


Guidance & Commitments

CommitmentSpecificsTimeline
Double-digit growthConfident of double-digit growth for both API and nutraceuticals segments, volume-based and price-basedFY25
Kakinada Phase-I productionProduction activity to gradually begin with validations and pre-chemistry productsDuring FY24-25
Kakinada revenue contributionRegulatory approvals and customer filings required before products reach market1-2 years after commercialization (FY26-27)
Future generics commercializationFilings planned for completion in the next few months, commercialization to followFY26
New product revenues (e.g., Ticagrelor)Patents expire from 2026, revenues to start flowing as products come off-patentFrom FY26
Asset turnoverImprove from 0.6-0.7 to one-to-one, driven by Kakinada capex and new API productsNext 2-3 years
Generic-to-CS revenue mixTarget 50:50 split, not heavy on either sideNo date
New CAPEX guidanceWill be provided after existing projects are completedNext quarter or the quarter after
Kakinada Phase-II considerationTriggered when utilization reaches ~90% (currently at 80-85%)Gated on utilization

Key Metrics

MetricQ1 FY25
Consolidated revenue₹2,197 cr, +18% YoY
Constant currency revenue growth18%
Material consumption40% of sales revenue, vs 39% in Q4 FY24 and 39% in Q1 FY24
Profit before tax₹604 cr, vs ₹492 cr in Q1 FY24
Profit after tax₹430 cr, vs ₹356 cr in Q1 FY24
Exports share86% of revenue
Exports to US and Europe70% of revenue
Generics to custom synthesis mix51%:49%
Forex impact₹1 cr loss, vs ₹3 cr gain in Q1 FY24
Nutraceuticals revenue₹178 cr, flat YoY
Capitalized assets during quarter₹60 cr
Capital work-in-progress₹1,062 cr, of which Kakinada project is ₹837 cr
Total spent on Kakinada project (incl. advances)₹1,018 cr
Cash on books₹4,229 cr as of June 30, 2024
Receivables₹1,942 cr
Maintenance capex guidance₹250–300 cr per year
Asset turnover0.6–0.7x currently, expected to reach 1x in 2–3 years